D
Daniel Aletaha
Researcher at Medical University of Vienna
Publications - 398
Citations - 51111
Daniel Aletaha is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 74, co-authored 298 publications receiving 43215 citations. Previous affiliations of Daniel Aletaha include National Institutes of Health & University of Vienna.
Papers
More filters
Proceedings ArticleDOI
SAT0194 Sirukumab integrated safety in rheumatoid arthritis patients: analysis of the sirround phase 3 data
Daniel Aletaha,Carter Thorne,Michael Schiff,M Harigai,R Rao,Neil Goldstein,B Cheng,C Cohen,B. Hsu,Kurt Brown +9 more
TL;DR: Sirukumab (SIR), a human monoclonal antibody that selectively binds the IL-6 cytokine, is in development for the treatment of rheumatoid arthritis, and there were more adverse events, AEs leading to discontinuation, and serious AEs with SIR vs pbo, with cumulative rates of SAEs remaining constant over time (Table).
Journal ArticleDOI
POS0701 LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO csDMARDs: RESULTS FROM RA-BEYOND UP TO 7 YEARS OF TREATMENT
Riccardo Caporali,Daniel Aletaha,Raimon Sanmartí,Tsutomu Takeuchi,D. Mo,Ewa Haładyj,Liliana Zaremba-Pechmann,P. Taylor +7 more
TL;DR: Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, has demonstrated efficacy in patients (pts) with rheumatoid arthritis (RA) for up to 3 years in a long-term extension study RA-BEYOND, and RRs for LDA and REM were about twice those of SDAI and CDAI.
Journal ArticleDOI
Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?
Daniel Aletaha,Josef S. Smolen +1 more
TL;DR: Concomitant use of glucocorticoids, with MTX may not be inferior to combination therapy of MTX with TNF-inhibitors, and a strategy recommended in current guidelines as a short-term bridging approach until MTX therapy exhibits its full efficacy.
Journal ArticleDOI
Op0126 infections and serious infections in the filgotinib rheumatoid arthritis program
James Galloway,Maya H Buch,Kunihiro Yamaoka,C. Leatherwood,A. Pechonkina,I. Tiamiyu,D. Jiang,L. Ye,R. Besuyen,Daniel Aletaha,Kevin L. Winthrop +10 more
TL;DR: The Janus kinase (JAK)-1 preferential inhibitor filgotinib (FIL) improved rheumatoid arthritis (RA) signs and symptoms in 3 phase (P)3 trials but like other RA therapies, JAK inhibition is associated with increased infection rates.
Journal ArticleDOI
Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti et al.
TL;DR: The results on applying a 2 cm cut-off for the patient global assessment (PGA) criterion of the Boolean remission criteria for rheumatoid arthritis within the setting of a real-world database confirm the data presented in the recent report based on a clinical trial population.